Navigation Links
BioMS Medical recognized at Scrip Awards 2008
Date:12/11/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of MS, in exchange for an US$87 million upfront payment, potential development and sales milestones up to US$410 million and escalating royalties on sales.

"We are honored to receive this award which recognizes the significance of the alliance between BioMS and our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "This partnership demonstrates a mutual commitment focused on developing an effective therapeutic option for patients with secondary progressive MS, a debilitating disease of global proportion for which there are limited treatment options."

    About The Scrip Awards 2008
    ---------------------------

The Scrip Awards, hosted by Informa Healthcare - one of the world's leading medical and scientific publishers - brings together hundreds of senior-level industry experts at one of the industry's most prestigious and hotly contested awards ceremony, to highlight the achievements of pharmaceutical companies throughout the year. For further information visit http://scripawards.com.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... transfer solution that makes it easy for organizations to send and gather large ... cumbersome FTP software or email file size limitations. , Using the same ...
(Date:5/23/2017)... ... May 22, 2017 , ... ... in San Diego, California, this August will feature high-level speakers on quantum ... vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting in ...
(Date:5/23/2017)... ... ... Cambridge Semantics , the leading provider of Big Data management and analytics ... in Boston May 23-25 with a featured speaker and solution demos of its ... also a finalist for the Best of Show award. , James LaPointe, Managing Director ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... meeting and educational conference of the American Association of Bioanalysts (AAB) and the ... Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory ...
Breaking Biology Technology:
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):